Taxotere is a plant alkaloid chemotherapy drug derived from the yew tree. Taxotere is used intravenously in patients with locally advanced or metastatic breast cancer (after failure of prior chemotherapy) and in conjunction with doxorubicin and cyclophosphamide in patients with operable node-positive breast cancer.
Unfortunately, it appears as though Taxotere is no more effective than its competitor, Taxol, and comes with a substantially higher risk of permanent hair loss. Some plaintiffs have alleged that the manufacturer, Sanofi-Aventis, knew of this additional risk but did not properly warn patients.
If you suffered hair loss as a result of taking Taxotere, the drug company may be liable for your injury. Fill out the form below, and an attorney will assess your case.
